255 related articles for article (PubMed ID: 8505410)
1. Suppression of experimental autoimmune myasthenia gravis by oral administration of acetylcholine receptor.
Wang ZY; Qiao J; Link H
J Neuroimmunol; 1993 May; 44(2):209-14. PubMed ID: 8505410
[TBL] [Abstract][Full Text] [Related]
2. B cell responses to acetylcholine receptor in rats orally tolerized against experimental autoimmune myasthenia gravis.
Wang ZY; Huang J; Olsson T; He B; Link H
J Neurol Sci; 1995 Feb; 128(2):167-74. PubMed ID: 7537794
[TBL] [Abstract][Full Text] [Related]
3. Suppression of experimental autoimmune myasthenia gravis by nasal administration of acetylcholine receptor.
Ma CG; Zhang GX; Xiao BG; Link J; Olsson T; Link H
J Neuroimmunol; 1995 Apr; 58(1):51-60. PubMed ID: 7537280
[TBL] [Abstract][Full Text] [Related]
4. T cell reactivity to acetylcholine receptor in rats orally tolerized against experimental autoimmune myasthenia gravis.
Wang ZY; Qiao J; Melms A; Link H
Cell Immunol; 1993 Dec; 152(2):394-404. PubMed ID: 8258147
[TBL] [Abstract][Full Text] [Related]
5. Suppression of experimental autoimmune myasthenia gravis and experimental allergic encephalomyelitis by oral administration of acetylcholine receptor and myelin basic protein: double tolerance.
Wang ZY; He B; Qiao J; Link H
J Neuroimmunol; 1995 Dec; 63(1):79-86. PubMed ID: 8557828
[TBL] [Abstract][Full Text] [Related]
6. B cell autoimmunity to acetylcholine receptor and its subunits in Lewis rats over the course of experimental autoimmune myasthenia gravis.
Wang ZY; Link H; Qiao J; Olsson T; Huang WX
J Neuroimmunol; 1993 Jun; 45(1-2):103-12. PubMed ID: 8331155
[TBL] [Abstract][Full Text] [Related]
7. Nasal tolerance in experimental autoimmune myasthenia gravis (EAMG): induction of protective tolerance in primed animals.
Shi FD; Bai XF; Li HL; Huang YM; Van der Meide PH; Link H
Clin Exp Immunol; 1998 Mar; 111(3):506-12. PubMed ID: 9528890
[TBL] [Abstract][Full Text] [Related]
8. Prevention of experimental autoimmune myasthenia gravis by manipulation of the immune network with a complementary peptide for the acetylcholine receptor.
Araga S; LeBoeuf RD; Blalock JE
Proc Natl Acad Sci U S A; 1993 Sep; 90(18):8747-51. PubMed ID: 8378359
[TBL] [Abstract][Full Text] [Related]
9. Depletion of CD8+ T cells suppresses the development of experimental autoimmune myasthenia gravis in Lewis rats.
Zhang GX; Ma CG; Xiao BG; Bakhiet M; Link H; Olsson T
Eur J Immunol; 1995 May; 25(5):1191-8. PubMed ID: 7774622
[TBL] [Abstract][Full Text] [Related]
10. Protective potential of experimental autoimmune myasthenia gravis in Lewis rats by IL-10-modified dendritic cells.
Duan RS; Adikari SB; Huang YM; Link H; Xiao BG
Neurobiol Dis; 2004 Jul; 16(2):461-7. PubMed ID: 15193302
[TBL] [Abstract][Full Text] [Related]
11. Synthetic peptides fail to induce nasal tolerance to experimental autoimmune myasthenia gravis.
Zhang GX; Shi FD; Zhu J; Xiao BG; Levi M; Wahren B; Yu LY; Link H
J Neuroimmunol; 1998 May; 85(1):96-101. PubMed ID: 9627002
[TBL] [Abstract][Full Text] [Related]
12. Mucosal tolerance to experimental autoimmune myasthenia gravis is associated with down-regulation of AChR-specific IFN-gamma-expressing Th1-like cells and up-regulation of TGF-beta mRNA in mononuclear cells.
Ma CG; Zhang GX; Xiao BG; Wang ZY; Link J; Olsson T; Link H
Ann N Y Acad Sci; 1996 Feb; 778():273-87. PubMed ID: 8610980
[TBL] [Abstract][Full Text] [Related]
13. Nasal tolerance to experimental autoimmune myasthenia gravis: tolerance reversal by nasal administration of minute amounts of interferon-gamma.
Li HL; Shi FD; Bai XF; Huang YM; van der Meide PH; Xiao BG; Link H
Clin Immunol Immunopathol; 1998 Apr; 87(1):15-22. PubMed ID: 9576006
[TBL] [Abstract][Full Text] [Related]
14. Oral administration of acetylcholine receptor: effects on experimental myasthenia gravis.
Okumura S; McIntosh K; Drachman DB
Ann Neurol; 1994 Nov; 36(5):704-13. PubMed ID: 7979216
[TBL] [Abstract][Full Text] [Related]
15. Use of complementary peptides and their antibodies in B-cell-mediated autoimmune disease: prevention of experimental autoimmune myasthenia gravis with a peptide vaccine.
Araga S; Blalock JE
Immunomethods; 1994 Oct; 5(2):130-5. PubMed ID: 7874437
[TBL] [Abstract][Full Text] [Related]
16. 'Split tolerance' induction by intrathymic injection of acetylcholine receptor in a rat model of autoimmune myasthenia gravis; implications for the design of specific immunotherapies.
Ohtsuru I; Matsuo H; Fukudome T; Suenaga A; Tsujihata M; Nagataki S
Clin Exp Immunol; 1995 Dec; 102(3):462-7. PubMed ID: 8536358
[TBL] [Abstract][Full Text] [Related]
17. Prevention of experimental autoimmune myasthenia gravis by a monoclonal antibody to a complementary peptide for the main immunogenic region of the acetylcholine receptors.
Araga S; Galin FS; Kishimoto M; Adachi A; Blalock JB
J Immunol; 1996 Jul; 157(1):386-92. PubMed ID: 8683141
[TBL] [Abstract][Full Text] [Related]
18. Prevention of experimental autoimmune myasthenia gravis in rats by fetal alpha-fetoprotein-rich fractions.
Brenner T; Zielinski A; Argov Z; Abramsky O
Tumour Biol; 1984; 5(5):263-74. PubMed ID: 6085187
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of experimental autoimmune myasthenia gravis by major histocompatibility complex class II competitor peptides results not only in a suppressed but also in an altered immune response.
Wauben MH; Hoedemaekers AC; Graus YM; Wagenaar JP; van Eden W; de Baets MH
Eur J Immunol; 1996 Dec; 26(12):2866-75. PubMed ID: 8977279
[TBL] [Abstract][Full Text] [Related]
20. Interferon gamma (IFN-gamma) is necessary for the genesis of acetylcholine receptor-induced clinical experimental autoimmune myasthenia gravis in mice.
Balasa B; Deng C; Lee J; Bradley LM; Dalton DK; Christadoss P; Sarvetnick N
J Exp Med; 1997 Aug; 186(3):385-91. PubMed ID: 9236190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
